UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington
, D.C.
20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): July 28, 2008
OCCULOGIX
,
INC.
(Exact
name of Registrant as specified in its Charter)
|
Delaware
(State
or other Jurisdiction of Incorporation)
|
000
51030
(Commission
File Number)
|
59-343-4771
(IRS
Employer Identification No.)
|
2600
Skymark Avenue, Unit 9, Suite 201
Mississauga,
Ontario L4W 5B2
(Address
of principal executive offices)
Registrant’s
telephone number, including area code:
(905)
602-0887
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
-
2 -
ITEM
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing
On July
28, 2008, the NASDAQ Listing Qualifications Panel (the “Panel”) notified
OccuLogix, Inc. (the “Company”) that the Panel has approved the transfer of the
listing of the Company’s common stock from The NASDAQ Global Market to The
NASDAQ Capital Market, effective at the opening of business on July 30,
2008. The Company had made a request for the transfer to the Panel on
June 27, 2008.
The
Panel’s grant of the Company’s request for the transfer of its listing to The
NASDAQ Capital Market is subject to the condition that, on or before August 29,
2008, the Company disclose, in a Current Report on Form 8-K, pro forma financial
statements evidencing stockholders’ equity of at least $2,500,000 or demonstrate
compliance with one of NASDAQ’s alternative listing criteria and the further
condition that, on or before September 16, 2008, the Company inform the Panel
that the Company’s common stock has evidenced a closing bid price of $1.00 or
more for a minimum of ten consecutive trading days. The Company’s
listing on The NASDAQ Capital Market is also contingent upon the successful
completion of an application and review process. The Company intends
to submit its transfer application to NASDAQ on or prior to August 4,
2008.
ITEM
9.01 Financial Statements and Exhibits
(d)
Exhibits
|
|
Press
Release of OccuLogix, Inc. dated July 29,
2008.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly
caused this Report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
OCCULOGIX,
INC.
|
|
Date:
July 29,
2008
|
By:
|
/s/Suh
Kim
|
|
|
|
Suh
Kim
General
Counsel
|